SUNESIS PHARMACEUTICALS INC
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Latest Form D
- $28.5M, Jul 2010
- Total capital
- $43.8M
- Federal grants
- $5.3M
- 22 awards · 1998–2005
- Private capital raised
- $38.5M
- 2 Form D · last Jul 2010
- 196 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 18
- 22 pending · first 2014
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$28.5M
- Private capital raisedForm D · SEC · 1st filing$10M
- Federal grantHealth and Human S · F32 · Identifying allosteric inhibitors of caspases$13K
- Federal grantHealth and Human S · Phase I · Caspase-1 Inhibitors Using Extended Tethering Technology$100K
- Federal grantHealth and Human S · Phase I · Bimodal PTP-1B Inhibitors using Tethering Technology$250K
- Federal grantHealth and Human S · Phase I · Bimodal PTP-1B Inhibitors using Tethering Technology$250K
- Federal grantHealth and Human S · Phase II · Development of Conformation Specific Kinase Inhibitors$750K
Show 17 earlier federal awards
- Federal grantHealth and Human S · Phase I · Development of Conformation Specific Kinase Inhibitors$100K
- Federal grantHealth and Human S · Phase II · Development of Conformation Specific Kinase Inhibitors$750K
- Federal grantHealth and Human S · Phase I · Covalent Tethering for Drug Discovery: Caspase-3$100K
- Federal grantHealth and Human S · Phase I · HIV Integrase Drug Discovery Using Tethering Technology$300K
- Federal grantHealth and Human S · Phase I · HIV Integrase Drug Discovery Using Tethering Technology$300K
- Federal grantHealth and Human S · F32 · Binding of Small Molecule Ligands to Protein Hot Spots$9K
- Federal grantHealth and Human S · F32 · Binding of Small Molecule Ligands to Protein Hot Spots$43K
- Federal grantHealth and Human S · F32 · Bicombinatorial discovery of small molecule tags$45K
- Federal grantHealth and Human S · F32 · Bicombinatorial discovery of small molecule tags$48K
- Federal grantHealth and Human S · F32 · Bicombinatorial discovery of small molecule tags$37K
- Federal grantHealth and Human S · F32 · Binding of Small Molecule Ligands to Protein Hot Spots$34K
- Federal grantHealth and Human S · Phase I · Fret Method For Identifying Hormone Antagonists$286K
- Federal grantHealth and Human S · Phase II · Site-directed Drug Discovery$1.1M
- Federal grantHealth and Human S · Phase I · Method For Drug Discovery Using Fragment Assembly$155K
- Federal grantHealth and Human S · Phase I · Method For Drug Discovery Using Fragment Assembly$109K
- Federal grantHealth and Human S · Phase II · Site-directed Drug Discovery$526K
- Federal grantHealth and Human S · F32 · Biologically Relevant Alpha Helix Stabilization$6K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
124months
from SUNESIS PHARMACEUTICALS INC’s first federal award to its first private round.
- First federal award · Dec 1998
- Health and Human S · $6K
- First Form D · Apr 2009
- $10M · 1st Form D
- Awards before first raise
- 22 awards
An association in public records, not a cause or a prediction.
Founders and team
From SEC Form D filings- Daniel N., Jr. SwisherExecutive Officer, DirectorNamed in SEC Form D filings
- David C. StumpDirectorNamed in SEC Form D filings
- Dayton MisfeldtDirectorNamed in SEC Form D filings
- Ed HurwitzDirectorNamed in SEC Form D filings
- Eric H. BjerholtExecutive OfficerNamed in SEC Form D filings
- Eric H. BjerkholtExecutive OfficerNamed in SEC Form D filings
Show all 11 people
- Helen Susan KimDirectorNamed in SEC Form D filings
- Homer L. PearceDirectorNamed in SEC Form D filings
- James W. YoungDirectorNamed in SEC Form D filings
- Matthew K. FustDirectorNamed in SEC Form D filings
- Steven B. KetchumExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 18 granted of 40- PendingPharmaceutical Formulations, Processes For Preparation, And Methods Of UseUSPTOApplication 16859111
- PendingPharmaceutical Formulations, Processes For Preparation, And Methods Of UseUSPTOApplication 16185793
- PendingStable SNS-595 Compositions And Methods Of PreparationUSPTOApplication 15951061
Show all 40 patent records
- Pharmaceutical Formulations, Processes For Preparation, And Methods Of UseDec 17, 2020 · Application 16859111Pending
- Pharmaceutical Formulations, Processes For Preparation, And Methods Of UseJun 13, 2019 · Application 16185793Pending
- Stable SNS-595 Compositions And Methods Of PreparationMar 21, 2019 · Application 15951061Pending
- Inhibitors Of Bruton's Tyrosine KinaseJan 29, 2019 · US 10,189,817Granted
- Heterocyclic PDK1 Inhibitors For Use To Treat CancerJan 17, 2019 · Application 15770369Pending
- SNS-595 And Methods Of Using The SameNov 1, 2018 · Application 15965741Pending
- SNS-595 And Methods Of Using The SameMay 29, 2018 · US 9,980,949Granted
- Stable SNS-595 Compositions And Methods Of PreparationMay 15, 2018 · US 9,969,730Granted
- Pyrimidinyl Tyrosine Kinase InhibitorsApr 17, 2018 · US 9,944,622Granted
- Methods Of Using (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC Acid For Treatment Of CancerApr 12, 2018 · Application 15714988Pending
- Substituted Pyrimidines For Inhibiting Raf Kinase ActivityMar 20, 2018 · US 9,920,048Granted
- Methods Of Using (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC Acid For Treatment Of Antecedent Hematologic DisordersDec 28, 2017 · Application 15642195Pending
- Method Of Preparing (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC AcidDec 12, 2017 · US 9,839,630Granted
- Bruton's Tyrosine Kinase InhibitorsOct 17, 2017 · US 9,790,229Granted
- SNS-595 And Methods Of Using The SameSep 12, 2017 · US 9,757,363Granted
- Methods Of Using (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC Acid For Treatment Of Antecedent Hematologic DisordersAug 8, 2017 · US 9,724,338Granted
- Methods Of Using SNS-595 For Treatment Of Cancer Subjects With Reduced BRCA2 ActivityJun 29, 2017 · Application 15233860Pending
- Compounds And Compositions For Treatment Of CancerJun 13, 2017 · US 9,676,774Granted
- Methods Of Using (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC Acid For Treatment Of Certain Hematologic DisordersMay 4, 2017 · Application 15173506Pending
- Inhibitors Of Bruton's Tyrosine KinaseApr 27, 2017 · Application 15167508Pending
- Heterocyclic Tyrosine Kinase InhibitorsFeb 2, 2017 · Application 15055910Pending
- Substituted 1,3-THIAZOLES As Synthetic Intermediates For Preparation Of Raf Kinase InhibitorsJan 31, 2017 · US 9,556,177Granted
- Methods Of Using (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC Acid In Combination TherapyNov 3, 2016 · Application 14958103Pending
- Stable SNS-595 Compositions And Methods Of PreparationOct 18, 2016 · US 9,469,635Granted
- Pyrimidinyl Tyrosine Kinase InhibitorsJul 19, 2016 · US 9,394,277Granted
- Inhibitors Of Bruton's Tyrosine KinaseMay 31, 2016 · US 9,353,087Granted
- Bruton's Tyrosine Kinase InhibitorsFeb 2, 2016 · US 9,249,146Granted
- Methods Of Using SNS-595 For Treatment Of Cancer Subjects With Reduced BRCA2 ActivityJul 23, 2015 · Application 14476606Pending
- Methods Of Using (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC Acid For Treatment Of Certain Hematologic DisordersJul 9, 2015 · Application 14461271Pending
- Method Of Preparing (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC AcidJun 11, 2015 · Application 14329765Pending
- Compounds And Compositions For Treatment Of CancerJun 4, 2015 · Application 14320414Pending
- SNS-595 And Methods Of Using The SameDec 25, 2014 · Application 14171673Pending
- SNS-595 And Methods Of Using The SameSep 2, 2014 · US 8,822,493Granted
- Method Of Preparing (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC AcidAug 12, 2014 · US 8,802,719Granted
- Compounds Useful As Raf Kinase InhibitorsAug 12, 2014 · US 8,802,657Granted
- Methods Of Using (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC Acid For Treatment Of CancerJul 24, 2014 · Application 14056877Pending
- Methods Of Using (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC Acid In Combination TherapyJul 24, 2014 · Application 13972800Pending
- Methods For Rapidly Identifying Small Organic Molecule Ligands For Binding To Biological Target MoleculesJun 26, 2014 · Application 13940020Pending
- Biaryl Inhibitors Of Bruton's Tyrosine KinaseApplication PCTUS2014069853Pending
- Biaryl Bruton's Tyrosine Kinase InhibitorsApplication PCTUS2014069839Pending
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .